TY - JOUR
T1 - Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study)
AU - Díez Valle, R.
AU - Slof, J.
AU - Galván, J.
AU - Arza, C.
AU - Romariz, C.
AU - Vidal, C.
AU - Valle Dr., Ricardo Díez
AU - i Rodriguez, Pilar Teixidor
AU - Martínez, Gloria Villalba
AU - Cabezudo Dr., Jose Manuel
AU - García Dr., Luis Miguel Bernal
AU - Sánchez Dr., Josep J.González
AU - Rodríguez Dr., Enrique Ferrer
AU - Sánchez Dr., Miguel Ángel Arraez
AU - Granados Dr., Gonzalo Olivares
AU - Delgado Dr., Álvaro Toledano
AU - Bertrán Dr., Gerardo Conesa
AU - Martín Dr., Juan José Acebes
AU - Ahicart Dr., Gerard Plans
AU - Díaz Dr., Avelino Parajón
AU - Asunción Dr., Carlos Botella
AU - Acin Dr., Ricardo Prat
AU - de Pedro, Marta del Álamo
AU - Urzaiz Dr., Luis Ley
AU - Barcia Dr., Juan A.
AU - Brin Dr., Juan R.
AU - Campa-Santamarina Dr., José María Torres
AU - Sánchez Dr., Ángel Maíllo
AU - Peña Dr., Jesús Merino
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Objective: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). Material and methods: Retrospective review of data from 18 neurosurgery departments that were categorised as either using or not using 5-ALA. The study included adult patients with suspected malignant gliomas for whom the intended treatment plan included complete resection followed by radiotherapy and chemotherapy with temozolomide. Postoperative MRI and clinical data representing at least 6 months were required for inclusion. Rates of CR and PFS6 were compared between patients with 5-ALA treatment and those without. Results: The study included 251 evaluable cases. CR and PFS6 rates were significantly higher in the group of patients treated surgically with 5-ALA: CR, 67% versus 45%, p=.000; PFS6 for patients with grade IV tumours, 69% versus 48%; p=.002. The differences retained their significance and magnitude after adjusting for all covariates including age, functional status, and whether gliomas were located in eloquent areas. Conclusions: In this retrospective series, use of 5-ALA during habitual surgical procedures in Spain was associated with a higher complete resection rate for malignant glioma and increased PFS6 for grade iv glioma. © 2013 Sociedad Española de Neurología.
AB - Objective: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). Material and methods: Retrospective review of data from 18 neurosurgery departments that were categorised as either using or not using 5-ALA. The study included adult patients with suspected malignant gliomas for whom the intended treatment plan included complete resection followed by radiotherapy and chemotherapy with temozolomide. Postoperative MRI and clinical data representing at least 6 months were required for inclusion. Rates of CR and PFS6 were compared between patients with 5-ALA treatment and those without. Results: The study included 251 evaluable cases. CR and PFS6 rates were significantly higher in the group of patients treated surgically with 5-ALA: CR, 67% versus 45%, p=.000; PFS6 for patients with grade IV tumours, 69% versus 48%; p=.002. The differences retained their significance and magnitude after adjusting for all covariates including age, functional status, and whether gliomas were located in eloquent areas. Conclusions: In this retrospective series, use of 5-ALA during habitual surgical procedures in Spain was associated with a higher complete resection rate for malignant glioma and increased PFS6 for grade iv glioma. © 2013 Sociedad Española de Neurología.
KW - 5-aminolevulinic acid
KW - Complete resection
KW - Fluorescence image-guided surgery
KW - Glioblastoma
KW - Malignant glioma
KW - Progression free survival
U2 - 10.1016/j.nrl.2013.05.004
DO - 10.1016/j.nrl.2013.05.004
M3 - Article
SN - 0213-4853
VL - 29
SP - 131
EP - 138
JO - Neurologia
JF - Neurologia
IS - 3
ER -